About SPRAVATO®

See the SPRAVATO® Story

The first and only NMDA receptor antagonist approved for TRD in adults1

SPRAVATO® hypothesized mechanism of action (MOA)

SPRAVATO® hypothesized MOA

Learn more about the SPRAVATO® hypothesized MOA


SPRAVATO® clinical program overview

Studied in more than 1700 adult patients with treatment-resistant depression1

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS1,2

COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1

Nasal spray + oral AD

SPRAVATO® patient stories

Nicole's story

Nicole, 23, is a real patient with TRD and has been compensated for her time by Janssen Pharmaceuticals, Inc.

I’m no longer starting off the day sad and about to cry. 
With SPRAVATO®, I’m starting off at neutral, which is the best.

Robin’s story

Robin is a real patient with TRD and has been compensated for her time by Janssen Pharmaceuticals, Inc.

When you’re depressed, you forget about the little things you used to enjoy. I’m catching up on all of that now.

References

1.SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. February 2020.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.